It has been shown that in patients with type 2 diabetes (T2D) at high risk for cardiovascular
disease (CVD) who received Empagliflozine as compared with placebo had a lower rate of death
from cardiovascular causes, non-fatal MI, or non-fatal strokes as well as death from any
cause and hospitalization for heart failure.
This lower incidence of cardiovascular disease in individuals treated with selective
inhibitor of renal sodium-glucose co-transporters (SGLTs) has been associated with reduction
of blood levels of fibroblast growth factor 23 (FGF23) and with increase of blood levels of
Klotho.
Therefore we will investigate the blood levels of fibroblast growth factor 23 (FGF23) and of
Klotho in type 2 diabetic patients treated with Empagliflozine The investigators anticipate
that patients treated with Empagliflozine will have decreased levels of FGF23 and increased
levels of Klotho which would provide a good explanation for the beneficial cardiovascular
effects of selective inhibitors of renal sodium-glucose co-transporters (SGLTs)